| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41375-018-0209-7 |
| P698 | PubMed publication ID | 30038381 |
| P50 | author | Hermann Einsele | Q1610986 |
| Roman Hajek | Q63639209 | ||
| Francesca Gay | Q79780506 | ||
| Niels W C J van de Donk | Q87712098 | ||
| Maria Gavriatopoulou | Q88776018 | ||
| Ute Hegenbart | Q89376735 | ||
| Pieter Sonneveld | Q90143311 | ||
| Sonja Zweegman | Q92858507 | ||
| Christian Straka | Q92973626 | ||
| Benedetto Bruno | Q96123891 | ||
| Mario Boccadoro | Q98568600 | ||
| Athanasios Dimopoulos | Q26338766 | ||
| Giampaolo Merlini | Q37839101 | ||
| Efstathios Kastritis | Q43187559 | ||
| Evangelos Terpos | Q57015797 | ||
| P2093 | author name string | Monika Engelhardt | |
| Pellegrino Musto | |||
| Jo Caers | |||
| P2860 | cites work | Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia | Q80563613 |
| Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia | Q83757867 | ||
| Thalidomide for POEMS syndrome | Q83827655 | ||
| Bevacizumab therapy for POEMS syndrome | Q83929768 | ||
| Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen | Q84201369 | ||
| Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy | Q84235764 | ||
| MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia | Q85732520 | ||
| Rituximab intolerance in patients with Waldenström macroglobulinaemia | Q86602713 | ||
| Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia | Q87495207 | ||
| Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia | Q87946433 | ||
| Treatment of light chain deposition disease with bortezomib and dexamethasone | Q24658325 | ||
| Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine | Q26799238 | ||
| Ibrutinib in previously treated Waldenström's macroglobulinemia. | Q27853148 | ||
| Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | Q28201685 | ||
| Immunophenotypic analysis of Waldenstrom's macroglobulinemia | Q28201709 | ||
| Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis | Q28217930 | ||
| Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial | Q28286064 | ||
| Primary plasma cell leukemia 2.0: advances in biology and clinical management. | Q30243927 | ||
| Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study | Q30278687 | ||
| Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia | Q33382030 | ||
| How I treat plasma cell leukemia | Q33402555 | ||
| Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia | Q33414529 | ||
| Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. | Q33437577 | ||
| Outcomes of patients with POEMS syndrome treated initially with radiation | Q33794285 | ||
| First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction | Q33795363 | ||
| Primary plasma cell leukemia and autologous stem cell transplantation | Q33829100 | ||
| Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group | Q33956990 | ||
| POEMS syndrome | Q34006873 | ||
| Trends in survival of patients with primary plasma cell leukemia: a population-based analysis | Q34019590 | ||
| Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus | Q34106817 | ||
| Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis | Q34353682 | ||
| Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component | Q34485172 | ||
| Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. | Q34552588 | ||
| Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race | Q34580117 | ||
| The role of radiotherapy in the management of POEMS syndrome | Q34620383 | ||
| Treatment of POEMS syndrome with bevacizumab | Q34714907 | ||
| Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial | Q34903868 | ||
| Kidney dysfunction during lenalidomide treatment for AL amyloidosis. | Q35025410 | ||
| Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome | Q35067588 | ||
| Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | Q35116840 | ||
| A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue | Q35552353 | ||
| Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome. | Q35611648 | ||
| Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research | Q35742685 | ||
| Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature | Q35848803 | ||
| Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis | Q35886289 | ||
| Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis | Q36015183 | ||
| Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols | Q36185955 | ||
| Dangerous small B-cell clones. | Q36516158 | ||
| Natural history and outcome of light chain deposition disease | Q36519972 | ||
| Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements | Q36910372 | ||
| Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis | Q36938784 | ||
| Proliferative glomerulonephritis with monoclonal IgG deposits. | Q37330535 | ||
| Genetic aberrations and survival in plasma cell leukemia | Q37486780 | ||
| Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. | Q37676296 | ||
| Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience | Q37911050 | ||
| Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant | Q38050703 | ||
| Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. | Q38082246 | ||
| Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. | Q38376616 | ||
| How I treat extramedullary myeloma | Q38672673 | ||
| Primary Plasma Cell Leukemia: Identity Card 2016. | Q38781794 | ||
| Lenalidomide is safe and active in Waldenström macroglobulinemia. | Q38973119 | ||
| Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death | Q40362742 | ||
| Outcomes of patients with renal monoclonal immunoglobulin deposition disease | Q40533557 | ||
| Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia | Q40773209 | ||
| Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. | Q40781792 | ||
| A practical approach to the diagnosis of systemic amyloidoses. | Q41505050 | ||
| Unexpected bone marrow finding in a patient with pancytopenia after hematopoietic stem cell transplantation | Q42065087 | ||
| Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis | Q42292795 | ||
| Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study | Q42931881 | ||
| Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. | Q43050098 | ||
| Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis | Q43189700 | ||
| Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). | Q43923016 | ||
| Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia | Q44404066 | ||
| Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience | Q44507982 | ||
| Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group | Q44559311 | ||
| Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party | Q44962191 | ||
| Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia. | Q44991602 | ||
| Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis | Q46251291 | ||
| Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease | Q46538650 | ||
| Bortezomib in the treatment of AL amyloidosis: targeted therapy? | Q46892406 | ||
| The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). | Q47140962 | ||
| Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond | Q47283493 | ||
| Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience | Q48123471 | ||
| Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). | Q48137388 | ||
| Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. | Q48276787 | ||
| Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. | Q50743781 | ||
| Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. | Q50851104 | ||
| Plasma cell leukemia: update on biology and therapy. | Q52838137 | ||
| Progress in the Treatment of Primary Plasma Cell Leukemia. | Q53781542 | ||
| Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. | Q54337852 | ||
| Renal Monoclonal Immunoglobulin Deposition Disease: A Report of 64 Patients from a Single Institution | Q56658531 | ||
| High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | Q57218202 | ||
| Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study | Q57904277 | ||
| Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach? | Q57904322 | ||
| A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis | Q57904446 | ||
| Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients | Q58029880 | ||
| Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide | Q58030111 | ||
| Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine | Q58030328 | ||
| Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience | Q58051878 | ||
| Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone | Q58136617 | ||
| The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients | Q58190652 | ||
| Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival | Q58853078 | ||
| A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis | Q61657837 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1883-1898 | |
| P577 | publication date | 2018-07-23 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias | |
| P478 | volume | 32 |
| Q61454609 | Cardiovascular adverse events in multiple myeloma patients |
| Q64257450 | Germline Risk Contribution to Genomic Instability in Multiple Myeloma |
| Q60949296 | How I treat elderly patients with plasma cell dyscrasias |
| Q96348701 | The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma |
| Q97545594 | Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome |
Search more.